CD274 and neoplasm: Tumor cells within MPE can express programmed cell death protein 1 (PD-L1), and patients with PD-L1 positive (TPS ≥1%) effusions may derive better clinical benefit from immune checkpoint inhibitors (ICIs) than those with PD-L1 negative disease (20).